Drugs / EB-DTNB-NK
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07502287 | Mar 2026 → Mar 2027 expected | ganglioneuroblastoma, neuroblastoma | Beijing Biotech | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EB-DTNB-NK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07502287 ↗ |
| Route | Intravenous | “administered intravenously on Day 0” NCT07502287 ↗ |
| Target | CD276 | “dual-target CAR recognizing GD2 and B7-H3 (CD276)” NCT07502287 ↗ |